Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

Peter Buxton, whistleblower who compared Tuskegee syphilis study to Nazi atrocities, dies at 86

Born in Czechoslovakia to a Jewish father and Catholic mother, he sounded the alarm on an unethical study of Black men

(JTA) —

In the early 1960s, Peter Buxtun was tracing sexually transmitted infections for the U.S. Public Health Service in San Francisco when he wandered into the coffee room of his clinic. There he heard an older PHS officer talking about a study begun 30 years before.

What he heard alarmed him: Working with the Tuskegee Institute in Alabama, the government had recruited 399 Black men who had contracted syphilis. Although antibiotics became available in the 1940s that could treat the disease, federal health officials ordered that the drugs be withheld from the subjects in order to study the effects of the disease.

The revelation jogged something in Buxtun, who was born in what is now the Czech Republic to a Jewish father and a Roman Catholic mother. Buxtun grew up listening to tales of the Holocaust told by an uncle, a German officer who tried and failed to prevent Nazi soldiers from murdering civilians.

“I thought, we can’t be doing this,” Buxtun recalled, according to historian Susan Reverby. He made his way to the library where he studied the Nuremberg Doctors Trial and the Nuremberg Principles, ethical guidelines for medical treatment and research developed in the wake of the Nazis’ monstrous experiments on Jews and and other prisoners. Buxtun recalled, “It was toward the end of the evening in that library downtown, and I thought: I’ve got to do something.”

The report he wrote in November 1965 to the Centers for Disease Control and the PHS blew the whistle on one of the most notorious research projects in the history of U.S. public health. Although it would take five more years and an Associated Press exposé to bring his findings to light, Buxtun would demonstrate that the “Tuskegee Study of Untreated Syphilis in the Negro Male” was a shameful abuse of government authority and medical ethics.

The revelations led to Congressional hearings and a class-action lawsuit that resulted in a $10 million settlement and the study’s closure. In 1997, President Bill Clinton formally apologized for the study, saying it was “wrong — deeply, profoundly, morally wrong. It was an outrage to our commitment to integrity and equality for all our citizens.”

Buxtun died from Alzheimer’s disease in Rocklin, California, on May 18, although his passing was only reported this week. He was 86.

The results of his act of conscience were profound. The government put in place new rules about how it conducts medical research. Some African Americans remain reluctant to participate in medical research to this day.

In interviews, Buxtun would shrug off the accolades he later received for his whistleblowing, including from family members whose relatives had taken part in the study. “I don’t want to be embarrassed by an oversupply of compliments. I am who I am,” he told bioethicist Carl Elliott in 2017.

But he would go on to give presentations about the study and medical ethics, and win awards for his involvement in exposing the Tuskegee study. After leaving the Public Health Service he attended law school, travelled frequently, and collected and sold antiques.

Born in Prague, Peter Buxtun was a baby when the Sudetenland, the German-speaking part of Czechoslovakia, was ceded to Nazi Germany. Buxtun’s father immediately prepared the family to immigrate to the United States, where they settled on a farm in Oregon.

Buxtun attended the University of Oregon, and served in the U.S. Army as a combat medic. He was working as a social worker when he answered an ad for the PHS.

In addition to his advocacy he spent more than 20 years trying to recover his family’s properties confiscated by the Nazis, and was partly successful. He left no immediate survivors.

“Peter’s life experiences led him to immediately identify the study as morally indefensible and to seek justice in the form of treatment for the men,” Ted Pestorius, a deputy director at the CDC, said at a 2022 program marking the 50th anniversary of the end of the study. “Ultimately, he could not relent.”

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.